Logo image of CRNX

CRINETICS PHARMACEUTICALS IN (CRNX) Stock Fundamental Analysis

NASDAQ:CRNX - Nasdaq - US22663K1079 - Common Stock

37.35  +0.87 (+2.38%)

After market: 37.31 -0.04 (-0.11%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to CRNX. CRNX was compared to 572 industry peers in the Biotechnology industry. While CRNX has a great health rating, there are worries on its profitability. CRNX is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CRNX had negative earnings in the past year.
CRNX had a negative operating cash flow in the past year.
In the past 5 years CRNX always reported negative net income.
In the past 5 years CRNX always reported negative operating cash flow.
CRNX Yearly Net Income VS EBIT VS OCF VS FCFCRNX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 -50M -100M -150M -200M

1.2 Ratios

CRNX's Return On Assets of -29.65% is fine compared to the rest of the industry. CRNX outperforms 69.03% of its industry peers.
With a decent Return On Equity value of -33.36%, CRNX is doing good in the industry, outperforming 77.17% of the companies in the same industry.
Industry RankSector Rank
ROA -29.65%
ROE -33.36%
ROIC N/A
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
CRNX Yearly ROA, ROE, ROICCRNX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

CRNX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CRNX Yearly Profit, Operating, Gross MarginsCRNX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K -80K -100K

More info and screens

8

2. Health

2.1 Basic Checks

CRNX does not have a ROIC to compare to the WACC, probably because it is not profitable.
CRNX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, CRNX has more shares outstanding
There is no outstanding debt for CRNX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
CRNX Yearly Shares OutstandingCRNX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
CRNX Yearly Total Debt VS Total AssetsCRNX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 18.58 indicates that CRNX is not in any danger for bankruptcy at the moment.
CRNX has a better Altman-Z score (18.58) than 92.21% of its industry peers.
CRNX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 18.58
ROIC/WACCN/A
WACC11.11%
CRNX Yearly LT Debt VS Equity VS FCFCRNX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 0 200M 400M

2.3 Liquidity

CRNX has a Current Ratio of 16.38. This indicates that CRNX is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CRNX (16.38) is better than 90.44% of its industry peers.
A Quick Ratio of 16.38 indicates that CRNX has no problem at all paying its short term obligations.
The Quick ratio of CRNX (16.38) is better than 90.44% of its industry peers.
Industry RankSector Rank
Current Ratio 16.38
Quick Ratio 16.38
CRNX Yearly Current Assets VS Current LiabilitesCRNX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

More info and screens

5

3. Growth

3.1 Past

CRNX shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -2.47%.
Looking at the last year, CRNX shows a very negative growth in Revenue. The Revenue has decreased by -78.03% in the last year.
CRNX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.55% yearly.
EPS 1Y (TTM)-2.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
Revenue 1Y (TTM)-78.03%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Sales Q2Q%-100%

3.2 Future

The Earnings Per Share is expected to grow by 13.22% on average over the next years. This is quite good.
The Revenue is expected to grow by 160.91% on average over the next years. This is a very strong growth
EPS Next Y-2.27%
EPS Next 2Y-3.41%
EPS Next 3Y-7.77%
EPS Next 5Y13.22%
Revenue Next Year-62.37%
Revenue Next 2Y5.4%
Revenue Next 3Y109.63%
Revenue Next 5Y160.91%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
CRNX Yearly Revenue VS EstimatesCRNX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B 2B
CRNX Yearly EPS VS EstimatesCRNX Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CRNX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CRNX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CRNX Price Earnings VS Forward Price EarningsCRNX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CRNX Per share dataCRNX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6 8

4.3 Compensation for Growth

CRNX's earnings are expected to decrease with -7.77% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.41%
EPS Next 3Y-7.77%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CRNX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRINETICS PHARMACEUTICALS IN

NASDAQ:CRNX (1/17/2025, 8:00:01 PM)

After market: 37.31 -0.04 (-0.11%)

37.35

+0.87 (+2.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners92.39%
Inst Owner Change0.63%
Ins Owners1.76%
Ins Owner Change-0.6%
Market Cap3.46B
Analysts84
Price Target75.48 (102.09%)
Short Float %7.75%
Short Ratio9.38
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-5.32%
Min EPS beat(2)-7.29%
Max EPS beat(2)-3.35%
EPS beat(4)0
Avg EPS beat(4)-6.4%
Min EPS beat(4)-12.64%
Max EPS beat(4)-2.31%
EPS beat(8)0
Avg EPS beat(8)-6.4%
EPS beat(12)1
Avg EPS beat(12)-7.31%
EPS beat(16)2
Avg EPS beat(16)-7.17%
Revenue beat(2)0
Avg Revenue beat(2)-61.65%
Min Revenue beat(2)-100%
Max Revenue beat(2)-23.3%
Revenue beat(4)1
Avg Revenue beat(4)-19.44%
Min Revenue beat(4)-100%
Max Revenue beat(4)145.52%
Revenue beat(8)5
Avg Revenue beat(8)126.31%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.03%
PT rev (3m)5.14%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-0.34%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.31%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.27%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-17.48%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3333.82
P/FCF N/A
P/OCF N/A
P/B 4.16
P/tB 4.16
EV/EBITDA N/A
EPS(TTM)-3.73
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-2.2
FCFYN/A
OCF(TTM)-2.15
OCFYN/A
SpS0.01
BVpS8.98
TBVpS8.98
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -29.65%
ROE -33.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-36.99%
ROA(5y)-37.98%
ROE(3y)-41.35%
ROE(5y)-42.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 166.43%
Cap/Sales 361.21%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.38
Quick Ratio 16.38
Altman-Z 18.58
F-Score4
WACC11.11%
ROIC/WACCN/A
Cap/Depr(3y)214.72%
Cap/Depr(5y)143.85%
Cap/Sales(3y)64.19%
Cap/Sales(5y)101.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%4.95%
EPS Next Y-2.27%
EPS Next 2Y-3.41%
EPS Next 3Y-7.77%
EPS Next 5Y13.22%
Revenue 1Y (TTM)-78.03%
Revenue growth 3Y285.59%
Revenue growth 5Y10.55%
Sales Q2Q%-100%
Revenue Next Year-62.37%
Revenue Next 2Y5.4%
Revenue Next 3Y109.63%
Revenue Next 5Y160.91%
EBIT growth 1Y-47.83%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-54.8%
EBIT Next 3Y-26.4%
EBIT Next 5YN/A
FCF growth 1Y-95.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.18%
OCF growth 3YN/A
OCF growth 5YN/A